Dyne Therapeutics stock gains, Sarepta falls after muscular dystrophy trial results

Dyne Therapeutics Inc. shares (DYN) jumped 40% premarket on Wednesday after the company released new data from trials of two investigational treatments for genetic muscle disorders. The experimental treatment DYNE-101 showed early dose-dependent results in patients with myotonic dystrophy type 1, Dyne said in a release. In patients with Duchenne muscular dystrophy, meanwhile, the experimental therapy Dyne-251 surpassed the level of production of the muscle protein dystrophin reported for the current standard of care for the condition, Dyne said. The company said it expects to report data for multiple, higher-dose cohorts from both trials in the second half of this year. Shares of Sarepta Therapeutics Inc. (SRPT), whose medication Exondys 51 or eteplirsen is designed to treat the same type of Duchenne muscular dystrophy as Dyne-251, fell more than 4% premarket on Wednesday. There have been no head-to-head trials comparing Dyne-251 to eteplirsen, Dyne said in its release. Dyne shares have gained 11.6% over the past 12 months, while Sarepta shares are down 22.9%.

-Eleanor Laise

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

01-03-24 0819ET

Copyright (c) 2024 Dow Jones & Company, Inc.